Localized Wilms’ tumor in low-middle-income countries (LMIC): how can we get better?

Author:

Asfour Hosam Y.,Khalil Sahar A.,Zakaria Al-Shimaa,Ashraf El-Sayed,Zekri Wael

Abstract

Abstract Background Wilms’ tumor (WT) represents about 6% of all childhood cancers. The overall survival markedly improved to exceed 90% in developed countries, yet some studies from developing counties still have poorer outcomes. The aim of this study is to assess the clinical outcome and the different prognostic factors that influence the outcome of pediatric loco-regional WT cases treated at National Cancer Institute (NCI), Cairo University, Egypt. This is a retrospective study which included pediatric loco-regional WT patients presented between January 2008 and December 2017. Patients were followed up till June 2019. Results Ninety-two eligible patients were included. Median age was 3 years (range 1 month–9 years). Abdominal mass was the commonest presentation (72.8%). The 5-year EFS and OS of the whole group was 83.7% and 94.6% retrospectively. Despite having a similar EFS (84.8 vs. 82.6%), stage III patients had a significantly lower OS than those in stages I and II (89.1% vs. 100%, p value 0.024). Twelve patients had unfavorable histology and had a significantly lower EFS and OS than the patients with favorable histology (50 and 83.3% vs. 88.8 and 96.3%, p value < 0.001 and 0.043, respectively). Conclusion Loco-regional Wilms’ tumor cases treated in Egypt had OS nearly the same as in developed countries, but had a lower EFS than expected mainly stages I and II. The stage and histological type are the main factors influencing the survival, and further studies are needed to investigate nuclear unrest grades and proper management of such cases.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Reference25 articles.

1. Davidoff AM. Wilms tumor. Adv Pediatr Infect Dis. 2012 [cited 2019 Mar 24];59(1):247–267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22789581.

2. Hohenstein P, Hastie ND. Wilms’ tumor. Brenners Encycl Genet Second Ed. 2013:340–1.

3. Szychot E, Apps J, Pritchard-Jones K et al. Wilms’ tumor: biology, diagnosis and treatment. Transl Pediatr. 2014 [cited 2019 Mar 26];3(1):12–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26835318.

4. Smets AM, de Kraker J. Malignant tumours of the kidney: imaging strategy. Pediatr Radiol. 2010 [cited 2019 Mar 27];40(6):1010–1018. Available from: https://link.springer.com/article/10.1007/s00247-010-1584-z.

5. Kieran K, Anderson JR, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, et al. Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. J Pediatr Surg. 2012 [cited 2019 Mar 27];47(4):700–706. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22498384.

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3